BMN 673
Item No. 19782

CAS Registry No.: 1207456-01-6
Formal Name: (8S,9R)-5-fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-3H-pyrido[4,3,2-de]phthalazin-3-one
Synonym: Talazoparib
MF: C_{19}H_{14}F_{2}N_{6}O
FW: 380.4
Purity: ≥98%
UV/Vis.: λ_{max}: 255, 309 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly

**Laboratory Procedures**

BMN 673 is supplied as a crystalline solid. A stock solution may be made by dissolving the BMN 673 in the solvent of choice. BMN 673 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of BMN 673 in these solvents is approximately 0.25, 20, and 25 mg/ml, respectively.

BMN 673 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, BMN 673 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. BMN 673 has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

**Description**

BMN 673 is an orally available poly(ADP-ribose) polymerase (PARP) inhibitor with an IC\textsubscript{50} value of 0.57 nM.\textsuperscript{1} It similarly binds to PARP1 and PARP2 with K\textsubscript{i} values of 1.2 and 0.85 nM, respectively, but has no effect on PARG.\textsuperscript{1} BMN 673 selectively targets tumor cells with BRCA1, BRCA2, or PTEN gene mutations and elicits antitumor activity in xenografted tumors in mice.\textsuperscript{2}

**Reference**